ReviewMolecules (Basel, Switzerland)2025
Imidazole Hybrids: A Privileged Class of Heterocycles in Medicinal Chemistry with New Insights into Anticancer Activity.
Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Thieno[3,2-International journal of molecular sciences · 2026Review
- Privileged nitrogen heterocycles in anticancer drug discovery: recent advances on imidazole, indole, and pyrimidine scaffolds.RSC advances · 2026Review
- The State of Imidazolone as an Evolving Pharmacophore: Current Progress and Clinical Significance in Oncology and AMR.ACS omega · 2026Review
- Design, synthesis, and biological evaluation of novel imidazole-morpholinone hybrids as broad-spectrum antimicrobial agents: molecular docking, DFT, and ADMET studies.RSC advances · 2026Article
- Imidazole-Functionalized Thieno[3,2‑ACS omega · 2026Article
- Heterocycles in Medicinal Chemistry III.Molecules (Basel, Switzerland) · 2026Article
- Targeting cell cycle and apoptotic pathways with newly synthesized diselenide-linked imidazolone analogues with strong CDK6-targeting potential.RSC advances · 2026Article
- Synthesis and anticancer evaluation of novel thioimidazole derivatives bearing a trimethoxyphenyl moiety.Scientific reports · 2026Article
- Benzimidazole-Quinoline Hybrids: Synthesis and Antimicrobial Properties.Pharmaceuticals (Basel, Switzerland) · 2026Review
- FeACS omega · 2026Article
- Scaffold-Hopping Design and Synthesis of Thieno[3,2-International journal of molecular sciences · 2025Article
- Benzimidazole-Pyrimidine Hybrids: Synthesis and Medicinal Properties.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Pyrrolopyrimidines: Design, Synthesis and Antitumor Properties of Novel Tricyclic Pyrrolo [2,3-Molecules (Basel, Switzerland) · 2025Article
- Synthesis of Novel 7-Phenyl-2,3-Dihydropyrrolo[2,1-Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Imidazole is a five-membered heterocyclic system featuring two nitrogen heteroatoms at the 1- and 3-positions of the ring. The imidazole scaffold is particularly suited for kinase inhibition concepts. This further confirms that this scaffold is a privileged structure in the development of anticancer drugs. Considering these key factors and the recent focus of scientists on imidazole compounds, we discuss the anticancer activities of imidazole-containing hybrids and related compounds, highlighting articles published in 2023 that serve as a basis for medicinal chemistry leads. From a chemical perspective, the present review emphasizes hybrid molecules with an imidazole ring in the side chain, imidazole-centered hybrid molecules, condensed imidazole hybrids, hybrid compounds containing two or more imidazole rings, polycyclic imidazole hybrids, imidazole-containing metal complexes, and benzimidazole hybrids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.